Qualigen Therapeutics News

Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting

Qualigen Therapeutics, Inc. （Nasdaq: QLGN) today announces a poster presentation on its preclinical Novel Direct Pan-RAS Inhibitors was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 held April 5 – 10 in San Diego, California.

GlobeNewswireApr 10 20:00

Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience With QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting

CARLSBAD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. ("Qualigen" or the "Company," Nasdaq: QLGN) today announces that a poster featuring its early clinical experience wit

GlobeNewswireApr 9 20:00

Qualigen Therapeutics Ends Deal With Pan-RAS Holdings

TipRanksMar 29 04:25

12 Health Care Stocks Moving In Tuesday's Intraday Session

GainersJanux Therapeutics (NASDAQ:JANX) stock increased by 189.9% to $43.78 during Tuesday's regular session. The company's market cap stands at $2.0 billion. Viking Therapeutics (NASDAQ:VKTX) shares

BenzingaFeb 28 01:31

Qualigen Therapeutics Secures Investment and Expands Financing Options

TipRanksFeb 27 20:12

Qualigen Therapeutics Inks Exclusive RAS Program Deal

TipRanksFeb 23 05:25

Qualigen Therapeutics Provides Corporate Update For Q3 And To Date 2023

Initiated dosing of three patients in first cohort of Phase 1 clinical trial of QN-302 for treatment of advanced or metastatic solid tumorsPhase 1a patient recruitment ongoing; company anticipates sha

BenzingaNov 15, 2023 06:41

Qualigen Therapeutics Announces First Patient Dosed In The Phase 1a Clinical Trial Of QN-302 For Treatment Of Advanced Or Metastatic Solid Tumors

Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announces

BenzingaNov 7, 2023 21:33

12 Health Care Stocks Moving In Monday's Pre-Market Session

GainersMiromatrix Medical (NASDAQ:MIRO) stock rose 223.1% to $3.36 during Monday's pre-market session. The company's market cap stands at $91.7 million. Eargo (NASDAQ:EAR) stock rose 54.16% to $2.59.

BenzingaOct 30, 2023 21:05

Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer

Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announces a poster presentation on the Company's Pan-RAS platform at the American Association for Cancer Research (AACR) Special Conference in Breast Cancer Research, held October 19th to 22nd at the Westin San Diego Bayview.

GlobeNewswireOct 23, 2023 20:30

Qualigen Therapeutics Partners With TD2 For Phase 1 Clinical Development Of QN-302 For The Treatment Of Advanced Or Metastatic Solid Tumors

Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announced

BenzingaAug 17, 2023 20:33

Qualigen Therapeutics GAAP EPS of -$0.69, Revenue of $1.62M

Seeking AlphaAug 15, 2023 21:10

Earnings Flash (QLGN) QUALIGEN THERAPEUTICS Reports Q2 Revenue $1.6M

08:31 AM EDT, 08/15/2023 (MT Newswires) -- Earnings Flash (QLGN) QUALIGEN THERAPEUTICS Reports Q2 Revenue $1.6M

MT NewswiresAug 15, 2023 20:31

Qualigen Therapeutics 2Q Loss/Shr 69c >QLGN

Qualigen Therapeutics 2Q Loss/Shr 69c >QLGN

Dow JonesAug 15, 2023 20:30

Qualigen Gains IND Clearance for Solid Tumors Candidate

Seeking AlphaAug 1, 2023 22:24

Qualigen Therapeutics Announces US FDA IND Clearance To Initiate Phase 1 Clinical Trial Of QN-302 For Treatment Of Advanced Or Metastatic Solid Tumors

Investigational New Drug (IND) clearance transitions Qualigen Therapeutics from preclinical to clinical-stage company and demonstrates leadership in G4-targeting therapies for areas of high unmet need

BenzingaAug 1, 2023 20:31

Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announces today that the U.S. Food and Drug Administration (FDA) has cleared the Company's IND application for QN-302, a potential best-in-class small molecule G-Quadruplex (G4)-selective transcription inhibitor.

GlobeNewswireAug 1, 2023 20:30

Qualigen Therapeutics Divests FastPack Diagnostics Business

All cash deal with Chembio Diagnostics, a US Subsidiary of the French Diagnostics Company BIOSYNEX, SA, solidifies Qualigen's strategic priority on therapeuticsCARLSBAD, Calif., July 24, 2023 (GLOBE N

BenzingaJul 24, 2023 20:17

QLGN, INOD and EVLO Among Mid-day Movers

Seeking AlphaJul 19, 2023 01:23

Qualigen Therapeutics Offering Stock and Warrants

Qualigen Therapeutics Offering Stock and Warrants

Dow JonesJun 14, 2023 05:17